Synopsis
This book relates the experience of researching, planning, and conducting a scientific study into intercessory prayer (prayer for others). The purpose of the study was to ascertain whether the impact of prayer could be measured in a formal study, based on the large number of anecdotal reports of efficacy. The study was a prospectively randomized double-blind trial that added prayer by an established Christian prayer group to conventional therapy for cancer. The unique design feature was that the primary endpoint was a change in a validated scale of spiritual well-being. The patients were informed that they were participating in a study about spiritual well-being and quality of life but remained blinded to the intervention. The initial observation from the baseline data was that spiritual well-being made a unique contribution to quality of life. The final outcome of the study was that there was a statistically significant difference in spiritual well-being favoring the prayer group. Thebackground includes a fascinating review of the medical literature on the topic, which contains positive and negative studies that each attracts a vigorous debate about methodology, endpoints, and whether metaphysical phenomena can or should be studied using scientific methodology. The complementary and alternative medicine literature is also equivocal as to whether prayer, arguably the most common complementary medical therapy, should be included in the range of interventions grouped under that heading. In addition to reporting the background and results of the study, the book explores the reactions of a range of individuals to the trial, all of which help reflect on the nature of prayer.
About the Author
Ian Olver, MD, PhD, is a Fellow of the Royal Australasian College of Physicians, its Chapter of Palliative Medicine, and is a member of the Royal Australian College of Medical Administrators. He completed a PhD from Monash University in bioethics, exploring life and death issues, and a Certificate of Ministry at the Adelaide College of Divinity. He trained in medical oncology at Peter MacCallum Cancer Institute, the Alfred Hospital in Melbourne, and the University of Maryland Cancer Center in Baltimore. In 2006 he was appointed CEO, Cancer Council Australia, a Clinical Professor in the Department of Medicine at the University of Sydney, and he is an Honorary Associate, Department of Medical Oncology, Royal Prince Alfred Hospital. After serving on several ethics committees in Victoria and South Australia and the American society of Clinical Oncology Ethics Committee, and chairing the Cancer Institute NSW Research Ethics Committee for multicenter cancer trials, he now sits on the Australian Health Ethics committee of the NHMRC and chairs the Medical Oncology Group of the Australia Ethics Committee. In 2008 he was awarded the Cancer Achievement Aware by the Medical Oncology Group of Australia.
"About this title" may belong to another edition of this title.
